Diabetes Care, Vol 18, Issue 1 87-89, Copyright © 1995 by American Diabetes Association

ARTICLES

Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients

T Morise, Y Takeuchi, M Kawano, I Koni and R Takeda
Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.

OBJECTIVES--To elucidate the significance of plasma levels of endothelin (ET) and von Willebrand factor (vWF) as possible markers for endothelial dysfunction in non-insulin-dependent diabetes mellitus (NIDDM). RESEARCH DESIGN AND METHODS--Plasma levels of ET and vWF were determined in 22 NIDDM patients with or without retinopathy and 10 normal control subjects. RESULTS--The plasma levels of immunoreactive endothelin (irET) and vWF in NIDDM patients were 0.78 +/- 0.06 pmol/l and 218.3 +/- 18.4%, respectively, which represented significant (P < 0.05, P < 0.01, respectively) differences from the values in the control group (0.50 +/- 0.06 pmol/l and 139.1 +/- 11.1%, respectively, n = 10). However, when the diabetic patients were divided into two groups according to the presence or absence of diabetic retinopathy, the plasma levels of irET and vWF in the NIDDM patients with retinopathy were significantly higher (1.01 +/- 0.07 pmol/l and 283.0 +/- 21.4%, respectively, n = 12) compared with the control group and NIDDM patients without retinopathy (0.59 +/- 0.06 pmol/l and 164.3 +/- 17.0%, respectively). Plasma levels of irET showed a significant (P < 0.01) positive correlation with the levels of vWF. CONCLUSIONS--These data strongly suggest that increased plasma irET reflects the endothelial cell damage in NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Settergren, F. Bohm, L. Ryden, and J. Pernow Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease Eur. Heart J., July 2, 2008; 29(14): 1753 - 1760. [Abstract] [Full Text] [PDF]

				F. Bohm and J. Pernow The importance of endothelin-1 for vascular dysfunction in cardiovascular disease Cardiovasc Res, October 1, 2007; 76(1): 8 - 18. [Abstract] [Full Text] [PDF]

				S. Jesmin, S. Zaedi, N. Shimojo, M. Iemitsu, K. Masuzawa, N. Yamaguchi, C. N. Mowa, S. Maeda, Y. Hattori, and T. Miyauchi Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1030 - E1040. [Abstract] [Full Text] [PDF]

				A.-Y. Chong, A.D. Blann, and G.Y.H. Lip Assessment of endothelial damage and dysfunction: observations in relation to heart failure QJM, April 1, 2003; 96(4): 253 - 267. [Full Text] [PDF]

				K. J. Mather, B. Mirzamohammadi, A. Lteif, H. O. Steinberg, and A. D. Baron Endothelin Contributes to Basal Vascular Tone and Endothelial Dysfunction in Human Obesity and Type 2 Diabetes Diabetes, December 1, 2002; 51(12): 3517 - 3523. [Abstract] [Full Text] [PDF]

				R.J. Irving, J.P. Noon, G.C.M. Watt, D.J. Webb, and B.R. Walker Activation of the endothelin system in insulin resistance QJM, June 1, 2001; 94(6): 321 - 326. [Abstract] [Full Text] [PDF]

				R. A. Mangiafico, L. S. Malatino, M. Santonocito, R. S. Spada, F. A. Benedetto, and R.A. Mangiafico Plasma Endothelin-1 Release in Normal and Varicose Saphenous Veins Angiology, September 1, 1997; 48(9): 769 - 774. [Abstract] [PDF]